These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 8595647)

  • 1. Efficacy, tolerability, and effect on health-related quality of life of finasteride versus placebo in men with symptomatic benign prostatic hyperplasia: a community based study. CUSP Investigators. Community based study of Proscar.
    Byrnes CA; Morton AS; Liss CL; Lippert MC; Gillenwater JY
    Clin Ther; 1995; 17(5):956-69. PubMed ID: 8595647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and tolerability of finasteride in symptomatic benign prostatic hyperplasia: a primary care study. Primary Care Investigator Study Group.
    Tenover JL; Pagano GA; Morton AS; Liss CL; Byrnes CA
    Clin Ther; 1997; 19(2):243-58. PubMed ID: 9152564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT study). PROscar Safety Plus Efficacy Canadian Two year Study.
    Nickel JC; Fradet Y; Boake RC; Pommerville PJ; Perreault JP; Afridi SK; Elhilali MM
    CMAJ; 1996 Nov; 155(9):1251-9. PubMed ID: 8911291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of medical therapy on bother due to symptoms, quality of life and global outcome, and factors predicting response. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group.
    Lepor H; Williford WO; Barry MJ; Haakenson C; Jones K
    J Urol; 1998 Oct; 160(4):1358-67. PubMed ID: 9751354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term effects of finasteride in patients with benign prostatic hyperplasia: a double-blind, placebo-controlled, multicenter study. PROWESS Study Group.
    Marberger MJ
    Urology; 1998 May; 51(5):677-86. PubMed ID: 9610579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the efficacy and safety of finasteride in older versus younger men with benign prostatic hyperplasia.
    Kaplan SA; Holtgrewe HL; Bruskewitz R; Saltzman B; Mobley D; Narayan P; Lund RH; Weiner S; Wells G; Cook TJ; Meehan A; Waldstreicher J;
    Urology; 2001 Jun; 57(6):1073-7. PubMed ID: 11377309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of finasteride on health-related quality of life in men with symptomatic benign prostatic hyperplasia. Finasteride Study Group.
    Girman CJ; Kolman C; Liss CL; Bolognese JA; Binkowitz BS; Stoner E
    Prostate; 1996 Aug; 29(2):83-90. PubMed ID: 8700804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence and severity of sexual adverse experiences in finasteride and placebo-treated men with benign prostatic hyperplasia.
    Wessells H; Roy J; Bannow J; Grayhack J; Matsumoto AM; Tenover L; Herlihy R; Fitch W; Labasky R; Auerbach S; Parra R; Rajfer J; Culbertson J; Lee M; Bach MA; Waldstreicher J;
    Urology; 2003 Mar; 61(3):579-84. PubMed ID: 12639651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of finasteride on bother and other health-related quality of life aspects associated with benign prostatic hyperplasia. PLESS Study Group. Proscar Long-term Efficacy and Safety Study.
    Bruskewitz R; Girman CJ; Fowler J; Rigby OF; Sullivan M; Bracken RB; Fusilier HA; Kozlowski D; Kantor SD; Johnson EL; Wang DZ; Waldstreicher J
    Urology; 1999 Oct; 54(4):670-8. PubMed ID: 10510926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Can finasteride reverse the progress of benign prostatic hyperplasia? A two-year placebo-controlled study. The Scandinavian BPH Study Group.
    Andersen JT; Ekman P; Wolf H; Beisland HO; Johansson JE; Kontturi M; Lehtonen T; Tveter K
    Urology; 1995 Nov; 46(5):631-7. PubMed ID: 7495111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proscar: five-year experience.
    Moore E; Bracken B; Bremner W; Geller J; Imperato-McGinley J; McConnell J; Roy J; Tenover L; Vaughan D; Pappas F
    Eur Urol; 1995; 28(4):304-9. PubMed ID: 8575497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of finasteride on serum testosterone and body mass index in men with benign prostatic hyperplasia.
    Roehrborn CG; Lee M; Meehan A; Waldstreicher J;
    Urology; 2003 Nov; 62(5):894-9. PubMed ID: 14624915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Finasteride: an update of its use in the management of symptomatic benign prostatic hyperplasia.
    Wilde MI; Goa KL
    Drugs; 1999 Apr; 57(4):557-81. PubMed ID: 10235693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group.
    McConnell JD; Bruskewitz R; Walsh P; Andriole G; Lieber M; Holtgrewe HL; Albertsen P; Roehrborn CG; Nickel JC; Wang DZ; Taylor AM; Waldstreicher J
    N Engl J Med; 1998 Feb; 338(9):557-63. PubMed ID: 9475762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate tissue composition and response to finasteride in men with symptomatic benign prostatic hyperplasia.
    Marks LS; Partin AW; Gormley GJ; Dorey FJ; Shery ED; Garris JB; Subong EN; Stoner E; deKernion JB
    J Urol; 1997 Jun; 157(6):2171-8. PubMed ID: 9146609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group.
    Lepor H; Williford WO; Barry MJ; Brawer MK; Dixon CM; Gormley G; Haakenson C; Machi M; Narayan P; Padley RJ
    N Engl J Med; 1996 Aug; 335(8):533-9. PubMed ID: 8684407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sustained decrease in incidence of acute urinary retention and surgery with finasteride for 6 years in men with benign prostatic hyperplasia.
    Roehrborn CG; Bruskewitz R; Nickel JC; McConnell JD; Saltzman B; Gittelman MC; Malek GH; Gottesman JE; Suryawanshi S; Drisko J; Meehan A; Waldstreicher J;
    J Urol; 2004 Mar; 171(3):1194-8. PubMed ID: 14767299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term effects of doxazosin, finasteride and combination therapy on quality of life in men with benign prostatic hyperplasia.
    Fwu CW; Eggers PW; Kaplan SA; Kirkali Z; Lee JY; Kusek JW
    J Urol; 2013 Jul; 190(1):187-93. PubMed ID: 23357210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia.
    Stoner E
    Urology; 1994 Mar; 43(3):284-92; discussion 292-4. PubMed ID: 7510911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial.
    Kirby RS; Roehrborn C; Boyle P; Bartsch G; Jardin A; Cary MM; Sweeney M; Grossman EB;
    Urology; 2003 Jan; 61(1):119-26. PubMed ID: 12559281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.